Dr. Dattoli

POSTDOCTORAL TRAINING:

---

Special Fellow in Brachytherapy
Memorial Sloan-Kettering Cancer Center
and New York Hospital – Cornell University Medical Center
New York, New York
1989-1990

Radiation Oncology
New York University Medical Center/Bellevue Hospital Center
New York, New York
1986-1989

Internal Medicine
Albert Einstein College of Medicine
Bronx, New York
1985-1986

FACULTY APPOINTMENTS:

---

• Associate Professor, Memorial Sloan-Kettering Cancer Center (1990 – 92)
• Member, University of Cincinnati, Endo-Surgery Institute. (1990 – present)
• CRT Adjunct Faculty Member. (2018-present)
• Founding Clinical Faculty Member, Orlando College of Osteopathic Medicine. (2022-present)

OTHER SPECIALTY TRAINING:

---

External and Interstitial Hyperthermia (HIFU), Prostate Cryo Ablation
Memorial Sloan-Kettering Cancer Center New York, New York

BOARD CERTIFICATION:

---

Radiation Oncology, American College of Radiology

LICENSES:

---

Florida
California
New York

AWARDS:

---

• Tri-beta Biology Thesis Award, 1980
• Vassar College Academic Award, 1980

HONORS:

---

• Graduated Summa Cum Laude, Mt Sinai School of Medicine, NYC
• Special Honors: Internal Medicine, Obstetrics and Gynecology, Neurology and Radiology, 1983-1984
• Departmental Honors: Biology, 1980
• General Honors for Academic Excellence, 1980
• Phi Beta Kappa, 1980
• Highest Grade Point Average, (Valedictorian) Vassar, Class of 1980
• Dean’s List Honors, 1976-1980
• Alpha Kappa Psi, Man of the Year; 2008
• Leading Physicians of the World – top Brachytherapy Oncologist of the World; 2001-present
• Castle Connolly Top Doctors, 2015-present

SCHOLARSHIPS AND GRANTS:

---

• Mount Sinai School of Medicine Scholarship, 1981-1985
• National Institutes of Health Summer Fellowship Grant, Albert Einstein College of Medicine, 1983
• National Institutes of Health Summer Fellowship Grant, Albert Einstein College of Medicine, 1981
• Vassar College Scholarship, 1976-1980

INVESTIGATIVE APPOINTMENTS:

---

• Principal Investigator, COMPARE Registry, Sanofi-Synthelabo
• Principal Investigator, A Phase III, Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of 10 mg Astrasenten in Men with Non-Metastatic
• Hormone Refractory Prostate Cancer, Abbott Oncology (MOO-244)
• Principal Investigator, Pd-103 seed implant and single daily dosing of Uroxatral versus twice daily dosing of Flomax – A 3-month retrospective efficacy analysis.
• Sanofi-Aventis Medical Advisory Board, Brachytherapy and Radiation Oncology, Prostate Cancer Research Institute, Los Angeles, CA
• Medical Advisory Board PAACT (Patient Advocates for Advanced Cancer Treatments) Grand Rapids, MI
• Principal Investigator, Endovascular Brachytherapy. Theragenics and Johnson and Johnson
• Principal Investigator, Efficacy of Home Enteral Nutrition Support in Malnourished Patients Receiving Radiation Therapy Involving the Alimentary Tract: An Outcome • Study.
• Multicenter research protocol, IV Onyx-Harvard Research Foundation.

GOVERNMENT APPOINTMENTS:

---

• Member, Directors, Prostate Cancer Task Force, Tallahassee,FL.
• Consultant, Washington Oncology Roundtable Advisory Committee

COMMITTEES:

---

• Member, Medical Board, National Kidney Registry, 2007 – present
• Member, Board of Directors, American Brachytherapy Society, Chairman, America Brachytherapy Society Membership Committee 1996-2002.
• Member, Clinical Research Committee, American Brachytherapy Society Cancer Committee, New York University/Bellevue Hospital, 1987-1989
• Academic Council, Mount Sinai School of Medicine, 1982-1985

REVIEW BOARDS:

---

• Editorial Review Board, Journal of Brachytherapy, 2008-present
• Editorial Review Board, Journal of Urology, 2009-present
• Editorial Review Board, Journal of Radiotherapy and Oncology, 2009- present

PROFESSIONAL SOCIETIES:

---

• American College of Radiation Oncology
• American Society of Therapeutic Radiology and Oncology
• American Brachytherapy Society
• Chinese Kenpo Association of America (Medical Officer)

TEXTBOOKS:

---

• The Dattoli Blue Ribbon Prostate Cancer Solution – How to Survive and Thrive without Surgery. Dattoli, M., Cash, Jennifer; Dattoli Cancer Foundation 2009
• Prostate Brachytherapy Made Complicated, Dattoli, M, and Wallner, K., Blasko, J.: Third Edition, Smart Medicine Press, 2008
• Prostate Brachytherapy Made Complicated, Dattoli, M, and Wallner, K., Blasko, J.: Second Edition, Smart Medicine Press, 2001
• Prostate Brachytherapy Made Complicated, Dattoli, M, and Wallner, K., Blasko, J.: Smart Medicine Press, 1997
• Basic and Advanced Prostate Brachytherapy, Dattoli, Dicker, et al.; Palladium Brachytherapy: Rationale, Design and Evaluation ; Martin Dunitz and Parthenon Press, 2002

PATIENT GUIDE BOOKS:

---

•Hormonal Therapy for Prostate Cancer: The Benefits and Risks (revised); Dattoli, M 2017
•Interpreting Your PSA (revised); Dattoli, M, Undella, J 2018
•Coping With Prostate Cancer Recurrence (revised); Dattoli, M 2018
•Dosimetry and Radiotherapy for Prostate Cancer (revised); Dattoli, M, Fay, J 2018
•Conquering Prostate Cancer with DART and Brachytherapy; Dattoli, M 2018
•Image-Guided Prostate Biopsy: When, Why, and What to Expect (revised); Dattoli, M 2018
•Advanced Imaging for Prostate Cancer (revised); Dattoli, M 2018
•Dynamic Adaptive Radiotherapy for Prostate Cancer; Dattoli, M 2018
•The Dattoli Prostate Cancer Challenge: Evaluating All Your Treatment Options (revised); Dattoli, M 2018
• Lymph Node Positive Prostate Cancer, Dattoli, M 2018
• Radiation Safety and Prostate Cancer: Need You Be Concerned? Dattoli, M, Kaminski, J, 2017
• The Dattoli Challenge: Evaluating Your Prostate Cancer Treatment Options, Dattoli, M, Cash, J, 2011
• Hormonal Therapy: Will it Benefit Me? (Revised); Dattoli, M, Cash, J, 2010
• Color-Flow Doppler & Advanced Imaging for Prostate Cancer, Dattoli, M, Cash, J, 2010
• The Dattoli Blue Ribbon Prostate Cancer Solution:How to Survive and Thrive without Surgery; Dattoli, M, Cash, Jennifer: Dattoli Cancer Foundation 2009
• IMRT with DART and Brachytherapy, Dattoli, M, Cash, J 2009
• Intrepreting Your PSA (Revised), Dattoli, M, Cash, J, 2009
• Prostate Biopsy:When, Why and What to Expect, Dattoli, J, Cash, J, Fay, J, 2008
• Brachytherapy and IMRT, Dattoli, M., Cash, J, Kaltenbach, D 2005
• Hormonal Therapy: Will it Benefit Me?, Dattoli, M, Cash, J, Kaltenbach, D 2005
• Recurrence: What Do I Do Now?, Dattoli, M, Cash, J, Kaltenbach, D, 2005
• Interpreting Your PSA, Dattoli, M, Cash, J, Kaltenbach, D, 2005
• Dosimetry and Prostate Cancer: Precision Design for IMRT and Brachytherapy, Dattoli, M, Cash, J, Kaltenbach, D 2005-2010
• Surviving Prostate Cancer Without Surgery:The New Gold Standard Treatment that Can Save Your Life and Lifestyle. Dattoli, M, Cash, J and Kaltenbach, D Seneca House Press 2004
• Palladium Brachytherapy: Rationale, Design and Evaluation, Reprint excerpted from Basic and Advanced Prostate Brachytherapy, Dattoli Cancer Foundation, 2004

PATIENT INFORMATION PUBLICATIONS:

---

Dattoli, M, Carnahan, G; Prostate Gland Capsule: Fact or Fiction? DCF Journey Magazine - Fall 2019.

• Dattoli, M, Carnahan, G; Solving the Prostate Cancer Puzzle. PAACT Summer 2019
• Dattoli, M; Why Focal Therapies Won’t Work. DCF Journey Magazine- Fall 2017
• Dattoli, M; Recurrence, what now! Prostate Cancer Communication (PAACT) Volume 33: Number 2- Fall 2017.
• Dattoli, M, Carnahan, G; Testosterone: Friend or Foe? Prostate Cancer Communication (PAACT) Volume 32: Number 3- Summer 2016
• Dattoli, M: Active Surveillance: A Dark Side? Prostate Cancer Communication (PAACT) Volume 30: Number 4 – Winter 2014
• Myers, C, Dattoli, M, Bravo, S: Oligometastatic Prostate Cancer. PCRI Insights, Vol 15, No 1 2012 p 14-19
• Dattoli, M, America: Beware the UroRad. Choices – Prostate Cancer Communication, (PAACT). Volume 27, Number 2 – June 2011

MOST RELEVANT PROSTATE PUBLICATIONS:

---

•Dattoli, M, Kaminski, J., Kaminski, C. Replacing LNT: The Integrated LNT-Hormesis Model – Dose-Response: An International Journal – April – June 2020: 1-3
•Yun, R, Dattoli, M.J., Barentsz, J, Roach, Mack; Radiotherapy (RT) Guided by Ultra-Small Superparamagnetic Iron Oxide (USPIO) - Contrast MRI Staging for Patients With Advanced or Recurrent Prostate Cancer - ASCO-GU 28741, San Francisco - February 2020.
• Dattoli, M, Wallner, K, True, L, Bostwick, D, Cash, J & Sorace, R, Long-term Outcomes for Patients with Prostate Cancer having Intermediate and High-risk Disease, treated with Brachytherapy and Supplemental External Beam Radiotherapy. Journal of Oncology, Vol 2010, Article ID 471375, 6 pages
• Cash, J, Fay, J & Dattoli, M Combined Modality Treatment for Prostate Cancer with DART using 4D IG IMRT and Brachytherapy. Journal of Radiology Nursing, 28 (3) September 2009, pg 87-95
• Fang, Christine, Dattoli, M.J., Taira, Al, True, L, Sorace, R , Wallner, K, Prostatic Acid Phosphatase Adversely Impacts Cause-Specific Survival in Patients with Higher Risk Prostate Cancer Treated with Pd-103 Brachytherapy, J. Urology, 71 (1) 2008, pg 146-150
• Dattoli, M.J., Wallner, K, Cash, J., Sorace, R. Long-term Outcomes After Treatment with Brachytherapy and Supplemental Conformal Radiation for Prostate Cancer Patients having Intermediate and High-Risk Features,Cancer, Vol 110, No 3, pg 551-555
• Dattoli, M.J., Wallner, K, True, L.,Cash, J., Sorace, R. Long-term Prostate Cancer Control Using Pd-103 Brachytherapy and Beam Radiotherapy in Patients with a High Likelihood of Extracapsular Cancer Extension, Urology, Vol 69 (2), Feb 2007 pg 334-337
• Dattoli, M.J., Wallner, K, Merrick, G, et al, Reviving the Acid Phosphatase Test for Prostate Cancer, Oncology, Vol 21,No 8, July 2007
• Dattoli, M.J., Wallner, K, True, L.,Cash, J., Sorace, R. Long-term outcomes following EBRT + Pd-103 for higher risk prostatic carcinoma: influence of prostatic acid phosphates. Cancer, Vol 97, No 4, pg 979-983 February, 2003.
• Dattoli, M.J., Wallner, K., Sorace, R. Planned Extracapsular Seed Placement Using Palladium-103 For Prostate Brachytherapy. International Journal of Brachytherapy. 16: 35-43, April 2000.
• Dattoli, M.J., Nag S, et al; Recommendations for Transperineal Permanent Brachytherapy of Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics- Volume 44: pages 789-799- July 1999
• Dattoli, M.J., Wallner, K., True, L. Prognostic Role of Serum Prostatic Acid Phosphatase For Pd-103 Based Radiation For Prostatic Carcinoma. International J of Radiation-Oncology Biology and Physics 45: 1999.
• Dattoli, M.J., Wallner, K. Disease-Free Survival After External Beam Irradiation and Palladium-103 Brachytherapy Boost for High-Risk Prostatic Carcinoma. Int Journal of Brachytherapy 13:1-7, 1998.
• Wallner, K , Dattoli, M.J. Low Risk of Urinary Incontinence Following Prostate Brachytherapy in Patients with a Prior TURP. International Journal of Radiation Oncology , Biology and Physics 37:565-569,1997.
• American Brachytherapy Society Current Clinical Practice for Permanent Brachytherapy of Prostate, M. Dattoli, J. Blasko, G.Grado, Jl of Brachytherapy International; 10/1997; 13(3) 243-251
• Dattoli, M.J. “A Reply From Dr. Dattoli regarding High Risk Prostate Cancer Treated With Palladium-103” Int J Rad Onc Bio & Phy, 39: 755-756, 1997.
• Dattoli, M.J., Wallner, K. An Improved Method of Anchoring the Prostate During Interstitial Brachytherapy. Int J Rad Onc Bio & Phy , 38: 341-342, 1997.
• Cash, J.C., Dattoli, M.J. Management of the Patients Receiving Transperineal Pd-103 Implant. Oncology Nursing Forum 24 (8): 1361-1367, 1997.
• Nag, S., Baird, M., Blasko, J., Dattoli, M.J. American Brachytherapy Society (ABS) Consensus Guidelines for Permanent Brachytherapy of Prostate Cancer. Proceeding Amer Brachytherapy Society, May 1997.
• Wallner, K., Dattoli, M.J. Advances in Radiation Therapy for Prostate Cancer; Seed Implantation Therapy. Clinical Courier. 14 (5)L: March 1996
• Dattoli, M.J., External Beam Irradiation Combined with Palladium-103 Brachytherapy for High-Risk, Localized Prostatic Carcinoma. Int J Rad Onc Bio & Phy 35: 875-879, 1996
• Dattoli, M.J., Lautersztain, J., Mechanick, J. Nutritional Support in Cancer Patients Undergoing Aggressive Radiation Treatments. Nutrition and Clinical Practice 11:53-58, 1996.
• Armstrong, J.G, Dattoli, M.J., Minsky, B.D., Harrison, L.B., and Fortner, J. The Use of a Prosthetic Tissue Expander to Displace Bowel from a Brachytherapy Implant Site. Int J Rad Onc Bio & Phys 19: 1521-1524, 1992.
• Radiation Therapy for Intracranial Germinoma: The Case for Limited Volume Treatment. Int J Rad One Bio & Phy: 19:429-431, 1990 This was included to illustrate that Dr. Dattoli is very knowledgeable about Protons and the fact that their utility is primarily with small tumors of the brain (up to 8mm). When you increase the size of the target, such as with prostate cancer, the advantages associated with Protons become a very distinct disadvantage. Dr. Dattoli worked with Dr. Munzenrider on the Harvard Cyclotron (Protons) nearly 3 decades ago.)
• Dattoli, M.J, Gretz, H.F. 3rd, Beller U, et al. Analysis of multiple prognostic factors in patients with stage IB Cervical cancer: age as a major determinant. Int J Rad Onc, Bio & Phys 1989; 17:41-47. (This is very relevant as the Cervix is located in virtually the exact location in woman as the location of the prostate in men.)

RELEVANT ABSTRACTS & POSTER PRESENTATIONS:

---

• Dattoli MJ, Kaminski JM, Lawrence, G, Kaplon, D, Risk of urinary morbidity associated with photoselective vaporization of the prostate (PVP) in prostate cancer patients undergoing a combined radiotherapy regimen con¬sisting of dynamic adaptive radiotherapy (DART) and brachytherapy boost; American Society of Clinical Oncology (ASCO), Genitourinary Symposium, February, 2021. Reprinted as an Interactive Poster Presentation by the International Journal Hem-Onc, retrieved December, 2021 (https://www.hem-onc.org/poster-05-dattoli).
• Dattoli MJ, Bravo SM, Kaplon DM, Hayes M, Osorio A, Dycus PM, Kaminski J; Efficacy of Ferumoxytol as a Lymphatic Contrast Agent in Prostate Cancer. ASCO-GU, February 2018.
• Dattoli, M., Sorace, R., Bravo, S., Bostwick, D.; Prostate biopsies using both gray scale and 3D color flow power Doppler ultrasound (3DCFPDU). ASCO-GU, 14100 February 2015
• Dattoli, M.J., Bravo, S.M., Hayes, M., Posniak, R.A., Elenberger, M.C., Myers, C., Osorio, A., Efficacy of Feraheme as a Lymphatic contrast Agent in Prostate Cancer, RSNA, November 2014
• Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Safety and Efficacy of Feraheme as a Lympatic Contrast Agent. ASTRO Symposia. Atlanta, GA, October 2013
• Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Ferumoxytol as a Lymph Node Contrast Agent in Patients with Metastatic Prostate Carcinoma: Rad-Path Correlation, including presentation. ASTRO Symposia. Orlando, FL, February 2013
• Bravo, S.M., Dattoli, M.J. Myers, C.E., et al: Ferumoxytol as a Lymph Node Contrast Agent in Patients with Metastatic Prostate Carcinoma: Rad-Path Correlation, including presentation. RSNA, Chicago, Illinois, November 2012
• Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Potential for Feraheme as Lymphatic Contrast Imagine Agent. Submitted to RSNA November 2011.
• Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Safety of Ferumoxytol (Feraheme) in Patients with Prostate Carcinoma. Submitted to RSNA November 2011.
• Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Ferumoxytol as Lymph Node Contrast Agent in Patients with Metastic Prostate Carcinoma: Rad-Path Correlation. Submitted to RSNA November 2011.
• Dattoli, M.J., Wallner, K; True, L.; Cash, J.; Sorace, R.A.; Long-term outcomes (16 years) for patients with prostate cancer having intermediate and high-risk disease, treated with brachytherapy and supplemental conformal radiation. 09-AB-20158-ASCO-GU Genitourinary Cancer Symposium; Orlando, Florida; February 2009.
• Dattoli, M.J., Wallner, K; True, L.; Cash, J.; Sorace, R.A.; Long-term 13-year actuarial prostate cancer control with Pd-103 brachytherapy and beam radiation in patients with a high likelihood of extracapsular cancer extension. Int J Rad Onc Bio & Physics, Vol 63, Number 2, 2115, 2005.
• Dattoli, M.J., Sorace, R., Cash, J., Wallner, K. Biochemical Failure Rates Following Combination External Beam Radiation and Palladium- 103 Boost for Clinically Localized High Risk Prostate Cancer: 10 Year Results: Int J Rad Onc Bio & Phy 54; pg 38, 2002.
• Sorace, R., Dattoli, M.J., Low Dose (1000cGy) External Beam Radiation Followed Immediately by Pd-103 Brachytherapy For Patients Having Prostate Cancer and a Single High Risk Feature – Abstract RSNA 2003.
• Dattoli, M.J., Wallner, K, Palladium 103 Brachytherapy for Clinical T1/T2 Prostate Cancinoma. Int J. Rad Onc Bio & Phy Proceedings 39: 1011, 1997.
• Dattoli, M.J., Cash, J.C., Ross, R., Koval, J.M., Sorace, R.A. Neoadjuvant Hormone Therapy and Palladium-103 Brachytherapy for Locally Recurrent Prostate Cancer. Proc Amer Soc Clin Onc 1118, 1997.
• Dattoli, M.J. Conformal Brachytherapy Boost to External Beam Irradiation for Clinically Localized High Risk Prostate Cancer. Proceedings of the American Society of Therapeutic Radiology, Biology and Physics, October, 1995.
• Wasserman, S.G., Dattoli, M.J. CT Based Post-Implant Analysis of pre-planned Prostate Implants. Annual Meeting of American Brachytherapy Society, Arizona, December 1995.
• Dattoli, M.J. Update of Patients Treated with Palladium-103 for Localized Prostate Cancer: The Tampa Experience. Proceedings of the American Brachytherapy Society. 3-23, pg. 39, December, 1994.
• Dattoli, M.J. Prostatic Brachytherapy with Palladium-103 for Localized prostate Cancer. Report of PSA Response and Toxicity, Radiological Society of North America. 639:230, November 1994.
• Dattoli, M.J. Prostatic Brachytherapy Using Palladium -103 for Localized Prostate Cancer. Report of Results and Toxicity. Proceedings of the American Society of Clinical Oncology. 800: 1994.
• Dattoli, M.J. Ultrasound Guided Palladium-103 Implants for Treatment of Localized Prostate Cancer: A Preliminary Report. Proceedings of the American Urological Association, 1994.
• Dattoli, M.J. Transperineal Ultrasound Guided Palladium-103 Implantation for Treatment of Localized Prostate Cancer: Preliminary Report of Toxicity and Outcome as Measured by Decline of PSA. Annual Meeting American Endocurietherapy Society, 1993.
• Dattoli, M.J, Gretz, H.F., Lerch, I.A., Demopoulos, R.I. Fried, P.R. Cervical Cancer in the Young. ASTRO Abstract. Int J Rad Onc, Bio & Phys 15: 139-140, 1988.

ORAL PRESENTATIONS:

---

• Dattoli MJ, Bravo SM, Kaplon DM, Hayes M, Osorio A, Dycus PM, Kaminski J; Efficacy of Ferumoxytol as a Lymphatic Contrast Agent in Prostate Cancer. ASCO-GU, February 8, 2018, San Francisco.
• Dattoli, M.J., Bravo, S.M., Myers, C.E., et al; Safety and Efficacy of Feraheme as a Lympatic Contrast Agent. ASTRO Symposia. Atlanta, GA, October 2013
• Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Ferumoxytol as a Lymph Node Contrast Agent in Patients with Metastic Prostate Carcinoma: Node Contrast Agent in Patients with Metastatic Prostate Carcinoma: Rad-Path Correlation. ASTRO Symposia. Orlando, FL, February 2013
• “Winter Oncology Symposium” Johns Hopkins Hospital; Panama City, Republic of Panama, July 2012
• “Winter Oncology Symposium” Johns Hopkins Hospital; Panama City, Republic of Panama, July 2011
• “New Radiation Technology to Diagnose, Target and Treat Prostate Cancer” Us TOO International 20th Anniversary Symposium; Chicago, IL August 21,2012
• “Radiation Therapy for Prostate Cancer Update” Mount Sinai Medical Center, New York, NY, April 2010
• “Trends in Radiation Therapy for Prostate Cancer – It’s Evolutionary; It’s Revolutionary” 3rd Annual W.B. Ingalls Memorial Prostate Health and Cancer Seminar; Jupiter, FL, March 2010
• “Prostate Cancer Recurrence – Detecting and Addressing Using Advanced Technologies” Man-to-Man Regional Conference; Sarasota, FL, January 2009
• “Prostate Brachytherapy: Pre-, Intra-Op and Post-Op Planning and Dosimetry” Annual Multidisciplinary Cancer Seminar, University of Florida – Shands Hospital, Gainesville, Florida; July 2007
• Commencement Address and Discussion of “Advances in Prostate Brachytherapy, Staging and Treatment,” Johns Hopkins Hospital, Panama City, Republic of Panama; July 2007
• “MRI, CFD and other Novel Methods for PCa Staging and Treatment” and “Advances in Radiation Therapy” International Conference on Prostate Cancer, Reston, VA, October 2006
• “Long-term Outcomes (13 year actuarial) After Treatment with Brachytherapy and 3D-CRT for Patients with High-risk Prostate Cancer,” 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco. February 2006.
• “Prostate Cancer and Radiation Methods using 4D IG-IMRT and Brachytherapy: The State of the Art,” Annual Central American Cancer Symposium, Republic of Panama, December 2005.
• “Advances in Radiation Therapy: Brachytherapy, Conventional EBRT to 3D-CRT to IMRT to 4D IG-IMRT and Beyond” Kingston Prostate Cancer Forum, Kingston, NY October 2005.
• “Advances in Radiation Therapy” National Conference on Prostate Cancer, Washington, DC June 2005.
“• Advances in Prostate Cancer Brachytherapy,” Annual Central American Cancer Symposium, Republic of Panama, December 2004.
• “Implant Alone VS. Combination Radiation Therapy for Localized Prostate Cancer” Shoot-out at Stone Mountain, Stone Mountain, GA., March 19-20, 2004.
• “Alpha-blockers as Contemporary Management of Benign Prostatic Hyperplagic” Consensus Meeting Amongst Thought Leaders; Orlando, FL, February 6-8, 2004.
• “Brachytherapy and IMRT” and “Radiation for Salvage” National Conference on Prostate Cancer – 2003” Burbank, California September 5-7, 2003.
• “Biochemical Failure Rates Following Combination External Beam Radiation and Palladium-103 Boost for Clinically Localized High Risk Prostate Cancer: 10 Year Results” Annual ASTRO Meeting, New Orleans, October 11-15, 2002.
• “Prostate Cancer: Present, Past and Future” Kingston Prostate Cancer Forum – Honorary Guest Speaker; Kingston, NY October 15, 2001.
• “Advances in Brachytherapy”. National Conference on Prostate Cancer 2000, Prostate Cancer Research Institute, Long Beach, California. October 13-15, 2000.
• “Palladium-103 Update – The Tampa Experience”. Annual ASTRO meeting San Antonio, Texas. November 1-2, 1999.
• “PAP, the PSA and Prostate Cancer.” American Society of Clinical Pathologist Annual Meeting, Dallas, Texas. September 1998
• “Prostate Cancer and Transperineal Brachytherapy: The State of the Art.” Ninth Annual Symposium: Pacific Northwest Cancer Institute, Seattle, Washington. June12-13, 1998.
• “Planned Extra-Capsular Seed Placement for Prostate Brachytherapy.” American Brachytherapy Society Annual Meeting, Albuquerque, New Mexico. May 30-31, 1998.
• First Symposium Internacional – “Advances in Prostate Cancer.” Sao Paolo, Brazil. November 28-December 2, 1997.
• “Pd-103 Brachytherapy for Clinical T1/T2 Prostate Carcinoma” 39th Annual ASTRO Meeting. Orlando, Florida. October 19-22, 1997.
• New Jersey Prostate Cancer Forum. “Prostate Cancer Today and Tomorrow.” Morristown, New Jersey. September 27, 1997.
• Florida Prostate Cancer Forum. “What Every Man and His Family Needs To Know.” Tampa, Florida. September 13, 1997.
• “Options for Prostate Cancer.” Florida Academy of Family Physicians-Summer Break Away. Orlando, Florida. July 10-13, 1997.
• “University Community Hospital Experience and Results.” Eighth Annual Symposium – Transperineal Brachytherapy for Early Stage Prostate Cancer: The State of the Art. Seattle, Washington. June 12-13, 1997.
• “Neoadjuvant Hormone Therapy and Palladium-103 Brachytherapy as Salvage for Locally Recurrent Prostate Cancer.” American Society of Clinical Oncology Annual Meeting. Denver, Colorado May 17-20, 1997.
• “Pd-103 Brachytherapy for Localized Prostate Cancer: The Tampa Experience.” Prostate Brachytherapy and New Therapeutic Strategies in the Management of Early Stage and Locally Advanced Prostate Cancer. Mount Sinai Medical Center, New York City . March 6-7, 1997.
• “Brachytherapy: Intraprostatic Seeds Using Pd-103.” Southwest Regional Cancer Conference: Fort Myers, Florida. October 1996.
• “Prostate Brachytherapy”. New York Prostate Cancer Forum. Kingston, New York. September 1996.
• “Brachytherapy for Treatment of Prostate Cancer.” Latin American Medical Society. Clearwater, Florida. August 1996.
• “Pd-103 Brachytherapy for Localized Prostate Cancer: The Tampa Experience.” Seventh Annual Symposium-Prostate Transperineal Brachytherapy: The State of the Art. Seattle, Washington, June, 1996.
• “Nutrition Support in Patients Undergoing Aggressive Radiation Treatment.” Annual Meeting of American Society for Parenteral and Enteral Nutrition, Washington, D.C. January 1996.
• “Conformal Brachytherapy Boost to External Beam Irradiation for Clinically Localized High Risk Prostate Cancer.” Annual Meeting of the American Society of Therapeutic Radiology, Biology and Physics, Miami, Florida. October 1995.
• “Update of Patients Treated with Palladium-103 for Localized Prostate Cancer: The Tampa Experience.” Annual Meeting American Brachytherapy Society. December 1994.
• “Prostatic Brachytherapy with Palladium-103 for Localized Prostate Cancer: Report of PSA Response and Toxicity.” Annual Meeting, Radiologic Society of North America, Chicago, Illinois. November 1994
• “Ultrasound Guided Palladium-103 Radioactive Implants for the Treatment of Prostate Cancer.” Tampa Bay Annual Oncology Update: Cancer of the Prostate. Tampa, Florida. October 1994.
• “Transperineal Ultrasound and Fluoroscopic Guided Palladium-103 Implants for the Treatment of Prostate Cancer.” International Meeting of the American Urological Association, London, England. October 1994.
• “Transperineal Palladium-103 Implants for Localized Prostate Cancer.” Annual Meeting of American Endocurietherapy Society, “Radiation Therapy and Breast Cancer Conservation.” Annual Oncology Update: Breast Cancer – State of the Art Annual Symposium, Tampa, Florida. September 1993.
• “High Dose Rate Brachytherapy: Clinical Applications.” Palm Beach Cancer Conference, Good Samaritan Medical Center, Palm Beach, Florida. October 1992.
• “Radiation Therapy/High Dose Rate Brachytherapy.” Annual Oncology Update: Gynecological Cancer, Tampa, Florida. September 1992.
• “Radiation Therapy for Intracranial Germinoma: The Case for Limited Volume Treatment.” Annual Meeting of the American Society of Therapeutic Radiologists, San Francisco, California. October 1989.
• “Multifactorial Analysis of Prognostic Factors in Patients with Stage lB Carcinoma of the Cervix: Age as a Major Determinant.” Annual Meeting of the American Society of Therapeutic Radiologists, New Orleans, Louisiana. October 1988.

Ongoing Collaborative Study Groups:

---

HOSPITAL AFFILIATIONS:

---

• University of Washington, Seattle
• University of California, San Francisco
• University of Nijmegan, The Netherlands
• Doctor’s Hospital of Sarasota, FL – active staff
• H. Lee Moffitt Cancer Center, Tampa, FL – consulting

---